John Beran- CEO
John received a bachelor’s of administration degree from the University of Wisconsin-Milwaukee. John began his professional career with KPMG where he worked for 8 years with clients ranging from manufacturing to health care. John left KPMG to join Aurora Health Care during a five year rapid growth period where Aurora expanded from a $400 million dollar system to over $ 2 billion in annual revenues. John served as the chief financial officer of several entities simultaneously as well as heading up two new divisions.   John was than recruited to SpectraCare in Louisville, Kentucky where he rose to the level of Vice President of Operations with over 1,200 employees.  SpectraCare was intending on going public but suffered many setbacks inflicted by the balanced budget act of 1997.  John played a strategic role in the company including authoring and implementing a restructuring plan. John left the company in 1999 to begin a consulting practice.

Starting with a consulting practice, John worked in several industries including the film industry (feature films), venture capital management and bio-technology business development serving as an advisor to senior management.  Eventually he decided to actively seek technologies that he thought had potential and begin start-ups. Scout Diagnostics was founded by John along with the patent holders, Dr. Mark Lovell and Dr. Bert Lynn.

Dr. Mark Lovell
Dr. Lovell is an Associate Professor in the Department of Chemistry at the University of Kentucky and received his PhD in Chemistry in 1992.  Dr. Lovell has published over 65 peer reviewed articles in the area of neurological disorders.  Dr. Lovell developed the initial ELISA test kit that demonstrated the feasibility of the aberrant protein complex to be used as a diagnostic tool.  Dr. Lovell continues to work on demonstrating the utility and effectiveness of Scout's diagnostic tool.  As a respected researcher in the field, Dr. Lovell has been able to gain access to the materials that are required to demonstrate the effectiveness of Scout's first diagnostic for Alzheimer's disease.   Having worked in the area of neurological disorders since 1992, Dr. Lovell understands the complexities of making a positive diagnosis for Alzheimer’s disease, and also understands the importance of such a diagnosis. 

Dr. Bert Lynn
Dr. Lynn is a Professor in the Department of Chemistry at the University of Kentucky and serves as the Director of the University of Kentucky Mass Spectrometry Facility.  Dr. Lynn has been working in the area of neurological disorders since 2001.  His experience with Mass Spectrometry has provided Scout with tools needed to discover and characterize new diagnostic targets.  Dr. Lynn brings an entrepreneurial optimism to the scientific team.  His inspiration to seek aberrant peptides as diagnostic tools for Alzheimer’s disease began the scientific team on the path to Scout Diagnostics.  With Dr. Lynn’s enthusiasm and Dr. Lovell’s healthy skepticism, the two researchers have formed a highly synergistic team.